Document Detail

Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia.
MedLine Citation:
PMID:  9401498     Owner:  NLM     Status:  MEDLINE    
SUMMARY: (1) Pretreatment endogenous serum Epo levels were relatively low in all patients studied with MM-associated anemia; (2) rHuEpo was well tolerated in these patients; (3) rHuEpo was highly effective in the treatment of anemia in MM, and (4) the response to rHuEpo is characterized by an increase in Hb levels, a reduction in BTR and an improvement in the WHO PS score.
M Mittelman; A Zeidman; Z Fradin; A Magazanik; U H Lewinski; A Cohen
Related Documents :
16755818 - Open splenectomy in jamaican children with sickle cell disease.
7508688 - Beta-s gene cluster haplotypes modulate hematologic and hemorheologic expression in sic...
15916058 - Case report post-splenectomy sepsis in thalassemic patients.
9401498 - Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia.
19659678 - Ketamine-associated bladder dysfunction.
15663678 - Unreliable residual volume measurement after increased water load diuresis.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Acta haematologica     Volume:  98     ISSN:  0001-5792     ISO Abbreviation:  Acta Haematol.     Publication Date:  1997  
Date Detail:
Created Date:  1998-01-08     Completed Date:  1998-01-08     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  0141053     Medline TA:  Acta Haematol     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  204-10     Citation Subset:  IM    
Department of Medicine B and Hematology Service, Rabin Medical Center, Golda, Hasharon, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Anemia / drug therapy*,  etiology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Blood Transfusion / utilization
Dose-Response Relationship, Drug
Erythropoietin / blood,  therapeutic use*
Hemoglobins / drug effects
Middle Aged
Multiple Myeloma / classification,  complications*,  drug therapy
Recombinant Proteins
Reg. No./Substance:
0/Hemoglobins; 0/Recombinant Proteins; 11096-26-7/Erythropoietin
Comment In:
Acta Haematol. 1998;100(2):115   [PMID:  9792950 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Recombinant erythropoietin trial in children with transfusion-dependent homozygous beta-thalassemia.
Next Document:  Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature.